Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Envisagenics to Bring RNA Splicing Software Platform to J&J Lung Cancer Initiative

Envisagenics to Bring RNA Splicing Software Platform to J&J Lung Cancer Initiative

Apr 21, 2020
|
staff reporter

NEW YORK – Envisagenics announced Tuesday it has entered into a research program agreement with Johnson & Johnson's Lung Cancer Initiative (LCI.)

Under the terms of the agreement, Envisagenics will build predictive models for lung cancer progression and risk and use its SpliceCore software platform to analyze LCI's data. 

Financial and other details were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Cancer

  1. Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

  2. Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

    Premium

  3. Stupid Strong Awards City of Hope $125K for Gastric Cancer Liquid Biopsy Research

  4. Cervical Cancer Study in Ugandan Women Finds HPV-Specific Tumor DNA Methylation, Gene Expression

  5. Oncocyte Provides Post-Mortem on DetermaDx Failure, Describes Renewed Focus on Remaining Assays

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.